Keywords: xeloda, plus, avastin, show, clinical, benefit, interim

Xeloda plus Avastin show clinical benefit

Article | 22 December 2006

Print This

An interim analysis of the XCALIBr trial suggests that first-line therapy with a combination of Swiss drug major Roche's anticancer ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in